secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2025-10-14T23:59:59+00:00
Accession:  0001615219-25-000145
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Salarius regains Nasdaq equity compliance; fully compliant ahead of Decoy merger
--------------------------------------------------------------------------------

- Received Nasdaq letter on Oct 10, 2025 confirming compliance with minimum stockholders' equity requirement (Rule 5550(b)(1)).
- Now fully compliant with all Nasdaq listing requirements, having also regained bid price compliance on Sept 9, 2025.
- Subject to a Mandatory Panel Monitor for one year from Oct 10, 2025; noncompliance could lead to delisting without a cure period.
- Planned merger with Decoy Therapeutics (announced Jan 13, 2025) remains on track; combined company to be named Decoy Therapeutics.
- Post-merger pipeline includes pan-coronavirus antiviral IND filing within 12 months and data from MD Anderson seclidemstat study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000145/0001615219-25-000145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000145/flks-20251010.htm
  HTML page:      https://secwatch.observer/filing/0001615219-25-000145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer